Related Experiment Videos
Immunogenicity and cross-allergenicity of aztreonam
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224.
Abstract:
Beta-lactams are responsible for more than half of the allergic drug reactions encountered in the hospital setting. Although most such reactions are mild, the potential for acute and life-threatening reactions cannot be underestimated when considering readministration of beta-lactam agents, such as the penicillins or cephalosporins, to persons who have previously exhibited sensitivity. In addition to concerns about possible allergic reactions to the beta-lactam antibiotics individually, considerable cross-reactivity has been demonstrated among such classes as the penicillins, the cephalosporins, and the imipenems, although it cannot yet be predicted on an individual basis. Early studies of the unique monocyclic beta-lactam--or monobactam--aztreonam, indicated that the new class demonstrated negligible cross-reactivity with the standard beta-lactams both experimentally and clinically.Further, aztreonam was associated with an extremely low (2 percent) incidence of immunologic drug reactions. Aztreonam also has been found to be well-tolerated by highly penicillin-allergic patients. Although further clinical study is indicated, data so far are encouraging. If it is confirmed that monobactams such as aztreonam are minimally cross-reactive, well-tolerated by subjects allergic to other beta-lactam antibiotics, and only weakly immunogenic, fewer allergic reactions may be associated with antimicrobial therapy in the future than have been seen with the other available beta-lactam antibiotic drugs.
Insights
Beta-lactam antibiotics cause many allergic drug reactions. Aztreonam, a monobactam, shows minimal cross-reactivity and low allergic reactions, offering a safer alternative for allergic patients.
Area of Science:
- Pharmacology
- Immunology
- Infectious Diseases
Background:
- Beta-lactam antibiotics, including penicillins and cephalosporins, are common causes of allergic drug reactions in hospitals.
- Significant cross-reactivity exists among different beta-lactam classes, complicating treatment for allergic individuals.
- Life-threatening reactions to beta-lactams necessitate careful consideration for patient readministration.
Purpose of the Study:
- To evaluate the cross-reactivity and immunogenicity of aztreonam, a monocyclic beta-lactam (monobactam).
- To assess the safety and tolerability of aztreonam in patients with known penicillin allergies.
Main Methods:
- Experimental and clinical studies were conducted to assess aztreonam's cross-reactivity with other beta-lactams.
- Incidence of immunologic drug reactions associated with aztreonam was recorded.
- Tolerability in penicillin-allergic patients was evaluated.
Main Results:
- Early studies indicate negligible cross-reactivity between aztreonam and standard beta-lactams.
- Aztreonam demonstrated an extremely low incidence of immunologic drug reactions (2%).
- Aztreonam was well-tolerated in patients with high penicillin allergy.
Conclusions:
- Aztreonam exhibits minimal cross-reactivity with other beta-lactam antibiotics.
- The low immunogenicity and good tolerability suggest aztreonam may reduce allergic reactions in susceptible patients.
- Further clinical studies are warranted to confirm aztreonam's safety profile in broader populations.